Great news for persons w/ #MASH cirrhosis in this ph2b study of #efruxifermin
Thoughts:
🤞it is a fair statement that longer rx may yield better results but that remains to be proven
the authors are to be 👏 for presenting ITT data. MASH studies needs to move away from “completer” analyses
#liversky